Admera Health has launched two new tests: PGxOnco for cancer supportive care, and LiquidGx, a suite of liquid biopsy-based tests for tumor profiling and drug resistance monitoring. The PGxOnco test includes 50 genes and about 200 variants, and provides recommendations for over 300 drugs via next-generation sequencing. LiquidGx represents a menu of both qPCR and a NGS tests that analyze tumor DNA in blood samples. PCR assays allows for the genotyping of ALK, BRAF, EGFR, and KRAS either individually or together. The NGS panel, aimed specifically at lung cancer, includes AKT1, BRAF, ERBB2, MET, RET, ALK, EGFR, KRAS, PIK3CA,and ROS1.